Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids ; day:19 ; month:12 ; year:2023 ; pages:1-16
Nature biomedical engineering ; (19.12.2023), 1-16
- Urheber
-
Harter, Marius F.
Recaldin, Timothy
Gerard, Regine
Avignon, Blandine
Bollen, Yannik
Esposito, Cinzia
Guja-Jarosz, Karolina
Kromer, Kristina
Filip, Adrian
Aubert, Julien
Schneider, Anneliese
Bacac, Marina
Bscheider, Michael
Stokar-Regenscheit, Nadine
Piscuoglio, Salvatore
Beumer, Joep
Gjorevski, Nikolche
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41551-023-01156-5
- URN
-
urn:nbn:de:101:1-2024030609340138638258
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Harter, Marius F.
- Recaldin, Timothy
- Gerard, Regine
- Avignon, Blandine
- Bollen, Yannik
- Esposito, Cinzia
- Guja-Jarosz, Karolina
- Kromer, Kristina
- Filip, Adrian
- Aubert, Julien
- Schneider, Anneliese
- Bacac, Marina
- Bscheider, Michael
- Stokar-Regenscheit, Nadine
- Piscuoglio, Salvatore
- Beumer, Joep
- Gjorevski, Nikolche
- SpringerLink (Online service)
Ähnliche Objekte (12)
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma
Novel T Cell-Engaging, Bispecific Antibodies for Depletion of Human Immunodeficiency Virus-Infected Cells
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
Bispecific antibodies
Bispecific antibodies
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma
Novel T Cell-Engaging, Bispecific Antibodies for Depletion of Human Immunodeficiency Virus-Infected Cells
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
Bispecific antibodies
Bispecific antibodies
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma
Novel T Cell-Engaging, Bispecific Antibodies for Depletion of Human Immunodeficiency Virus-Infected Cells
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
Bispecific antibodies
Bispecific antibodies
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells